Journal
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
Volume 20, Issue -, Pages S22-S28Publisher
WILEY
DOI: 10.1111/j.1440-1746.2005.04167.x
Keywords
acid-related disorders; consistent inhibition; CYP4502C19 genetic polymorphism; rabeprazole
Categories
Ask authors/readers for more resources
Amongst all the proton pump inhibitors (PPI), the hepatic metabolism of rabeprazole is least dependent on the CYP4502C19 system, Rabeprazole is therefore the PPI least affected by CYP4502C19 genetic polymorphism. This unique feature of rabeprazole complements rabeprazole's fast onset of action, and may lead to profound and consistent inhibition of gastric acid secretion in the treatment of acid-related disorders. (C) 2005 Blackwell Publishing Asia Pty Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
